HMGCR and metabolic dysfunction-associated steatotic liver disease: Increased expressions of hepatic HMGCR, an enzyme that limits cholesterol production, and SREBP2, a principal activator of HMGCR [49], were observed in NAFLD, whereas the expression of hepatic LDLR was decreased [48].